Product Information
SUMATRIPTAN 6 MG/0.5 ML AUTOINJ is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $62.9652 per ML under NDC 55111069312. Its NADAC has been published 636 times since May 28, 2014.
FDA first approved this application on Jan 29, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
6 mg/.5mL
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
55111069312
Classification
Generic
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
7/22/2026
Active Ingredients
SUMATRIPTAN SUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA090495FDA Approved
1/29/2014
TE Code
AB
On Market Since
2/24/2014
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN 6 MG/0.5 ML AUTOINJ has been published 636 times since May 28, 2014, and over the history we have for it it has declined 50.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $62.9652 per ML |
|---|---|
| All-time high | $153.0292 (Jan 11, 2017) |
| All-time low | $46.6942 (May 22, 2024) |
| 52-week high | $75.8160 |
| 52-week low | $62.9652 |
| Median price | $83.4202 |
| Average price | $94.2575 |
| Largest weekly change | +61.1% (Jun 19, 2024) |
| Weeks tracked | 636 |
| Tracking since | May 28, 2014 |
1W
N/A
1M
N/A
3M
-6.3%
6M
-8.8%
1Y
-9.5%
3Y
-5.5%
5Y
-10.3%
All
-50.6%
Last surveyed Jul 29, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 76% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sumatriptan Succinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN 6 MG/0.5 ML AUTOINJ?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN 6 MG/0.5 ML AUTOINJ, manufactured by Dr. Reddy's Laboratories Inc., is $62.9652 per ML (NDC 55111069312), effective Jul 29, 2026.
How has the price of SUMATRIPTAN 6 MG/0.5 ML AUTOINJ changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN 6 MG/0.5 ML AUTOINJ has declined 50.6%. It has been tracked across 636 weekly CMS publications since May 28, 2014.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN 6 MG/0.5 ML AUTOINJ?
Since May 28, 2014, the NADAC for SUMATRIPTAN 6 MG/0.5 ML AUTOINJ has ranged from a low of $46.6942 (May 22, 2024) to a high of $153.0292 (Jan 11, 2017), with a median of $83.4202 per ML.
Are there cheaper alternatives to SUMATRIPTAN 6 MG/0.5 ML AUTOINJ?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SUMATRIPTAN 6 MG/0.5 ML VIAL, is $15.0000 per ML — about 76% below SUMATRIPTAN 6 MG/0.5 ML AUTOINJ.
Who manufactures SUMATRIPTAN 6 MG/0.5 ML AUTOINJ?
SUMATRIPTAN 6 MG/0.5 ML AUTOINJ (NDC 55111069312) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.